BioChemics has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE (vaso-active lipid encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents.
John Masiz, president and CEO of BioChemics, said: “We continue to develop new transdermal delivery systems that target a variety of inflammatory and peripheral diseases.”